| __timestamp | Dynavax Technologies Corporation | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 26760000000 |
| Thursday, January 1, 2015 | 22180000 | 32169000000 |
| Friday, January 1, 2016 | 37257000 | 32339000000 |
| Sunday, January 1, 2017 | 27367000 | 32124000000 |
| Monday, January 1, 2018 | 64770000 | 33313000000 |
| Tuesday, January 1, 2019 | 74986000 | 35830000000 |
| Wednesday, January 1, 2020 | 79256000 | 36886000000 |
| Friday, January 1, 2021 | 100156000 | 41058000000 |
| Saturday, January 1, 2022 | 131408000 | 50684000000 |
| Sunday, January 1, 2023 | 152946000 | 61598000000 |
| Monday, January 1, 2024 | 67377000000 |
Infusing magic into the data realm
In the world of pharmaceuticals, the strategic allocation of Selling, General, and Administrative (SG&A) expenses can be a game-changer. Novo Nordisk A/S, a Danish multinational, and Dynavax Technologies Corporation, a U.S.-based biotech firm, offer a fascinating contrast in their financial strategies from 2014 to 2023. Novo Nordisk's SG&A expenses have consistently dwarfed those of Dynavax, reflecting its expansive global operations and marketing efforts. In 2023, Novo Nordisk's SG&A expenses were approximately 400 times greater than Dynavax's, highlighting its dominant market presence. Over the decade, Novo Nordisk's expenses grew by about 130%, while Dynavax saw an impressive 760% increase, albeit from a much smaller base. This growth trajectory underscores Dynavax's aggressive push to expand its market footprint. Understanding these financial dynamics provides valuable insights into each company's strategic priorities and market positioning.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or United Therapeutics Corporation
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Alkermes plc
Breaking Down SG&A Expenses: Novo Nordisk A/S vs ACADIA Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.